Brief: Verastem Oncology: Prelim Q4/2025 Rev And Business Updates; 2026 Priorities For Novel RAS/MAPK Pathway-Driven Cancer Portfolio
04/02/2026 12:40
Feb 4 (Reuters) - Verastem Inc VSTM.O: VERASTEM ONCOLOGY PROVIDES PRELIMINARY FOURTH QUARTER AND 2025 REVENUE AND BUSINESS UPDATES AND OUTLINES 2026 STRATEGIC PRIORITIES FOR NOVEL PORTFOLIO TARGETING RAS/MAPK PATHWAY-DRIVEN CANCERS VERASTEM INC - EXPECTS CASH RUNWAY INTO FIRST HALF OF 2027 VERASTEM - EXPECTS AVMAPKI FAKZYNJA CO-PACK NET PRODUCT REVENUES OF ABOUT $17.5 MILLION FOR Q4 OF 2025 AND APPROXIMATELY $30.9 MILLION FOR FULL YEAR 2025 VERASTEM INC - ANTICIPATES LGSOC COMMERCIAL LAUNCH AND DEVELOPMENT PROGRAM WILL BE SELF-SUSTAINING BY SECOND HALF OF 2026 VERASTEM INC - EXPECTS TO REPORT A TOPLINE READOUT OF PRIMARY ENDPOINT IN RAMP 301 TRIAL IN MID-2027 VERASTEM - TO ENGAGE WITH FDA IN 1H 2026 TO DISCUSS DEVELOPMENT PATH FORWARD, POTENTIAL REGISTRATION-DIRECTED CLINICAL TRIALS IN PDAC, NSCLC, AND CRC Source text: ID:nBw4jkTKYa Further company coverage: VSTM.O ((Reuters.Briefs@thomsonreuters.com;))